"Prednisone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
| Descriptor ID |
D011241
|
| MeSH Number(s) |
D04.210.500.745.432.719.702
|
| Concept/Terms |
Prednisone- Prednisone
- Dehydrocortisone
- delta-Cortisone
|
Below are MeSH descriptors whose meaning is more general than "Prednisone".
Below are MeSH descriptors whose meaning is more specific than "Prednisone".
This graph shows the total number of publications written about "Prednisone" by people in this website by year, and whether "Prednisone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 4 | 4 |
| 1996 | 1 | 4 | 5 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 5 | 6 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 3 | 4 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 5 | 6 |
| 2003 | 1 | 7 | 8 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 4 | 4 |
| 2006 | 1 | 6 | 7 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 8 | 8 |
| 2009 | 0 | 2 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 1 | 5 | 6 |
| 2012 | 0 | 4 | 4 |
| 2013 | 1 | 6 | 7 |
| 2014 | 0 | 9 | 9 |
| 2015 | 2 | 6 | 8 |
| 2016 | 2 | 5 | 7 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 4 | 4 |
| 2019 | 0 | 3 | 3 |
| 2020 | 1 | 6 | 7 |
| 2021 | 2 | 6 | 8 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 1 | 1 |
| 2024 | 2 | 2 | 4 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prednisone" by people in Profiles.
-
Successful Treatment of Double-Positive Rapidly Progressive Glomerulonephritis: A Case Report. J Investig Med High Impact Case Rep. 2025 Jan-Dec; 13:23247096251365418.
-
Impact of Abatacept Inclusive Graft-Versus-Host Disease Prophylaxis in Pediatric Stem Cell Transplantation for Hemoglobinopathy. Transplant Cell Ther. 2025 Oct; 31(10):826.e1-826.e10.
-
Impact of hydrocortisone vs prednisone therapy on postsurgical recovery in patients with endogenous hypercortisolism: a prospective cohort study. Eur J Endocrinol. 2025 Apr 30; 192(5):621-630.
-
Hematology-oncology provider perspectives regarding lymphoma treatment and cardioprotective strategies in patients with lymphoma at high risk for heart failure. Leuk Lymphoma. 2025 Aug; 66(8):1437-1446.
-
Treatment patterns and outcomes in follicular lymphoma with POD24: an analysis from the LEO Consortium. Blood Adv. 2025 Mar 11; 9(5):1013-1023.
-
Diffuse Large B-Cell Lymphoma/High-Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements: A Study of 60 Cases. Mod Pathol. 2025 May; 38(5):100710.
-
Real-world data on the clinical features, therapy patterns, and outcomes of older adults with diffuse large B-cell lymphoma in Latin America: A study from the Grupo de Estudio Latinoamericano de Linfoproliferativos (GELL). J Geriatr Oncol. 2025 01; 16(1):102160.
-
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2025 Oct; 88(4):359-369.
-
T-Cell-Rich Hodgkin Lymphoma With Features of Classic Hodgkin Lymphoma and Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Borderline Category With Overlapping Morphologic and Immunophenotypic Features. Arch Pathol Lab Med. 2024 Aug 01; 148(8):914-920.
-
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol. 2024 Sep; 11(9):e671-e681.